Galleri® Test: Summary

Galleri® Test

Healthcare, Diagnostics, Cancer Screening, Early Detection

The primary value offered is the ability to detect multiple types of cancer early, significantly improving treatment outcomes and potentially saving lives.

The Galleri® Test is a pioneering multi-cancer early detection (MCED) blood test that screens for various deadly cancers lacking recommended screening methods. It utilizes advanced methylation analysis to identify cancer signals in the bloodstream.

Multi-cancer early detection capability; Utilizes methylation patterns for detection; Machine-learning algorithms for predictive analysis; Focus on cancers without standard screening

Primary scenarios include routine health screenings, high-risk patient assessments, and proactive health management for individuals concerned about cancer.

First-of-its-kind multi-cancer early detection test; Advanced technology using methylation analysis; Focus on early detection for treatable cancers

Key strengths include innovative technology, a strong mission to reduce cancer mortality, and a focus on early detection that can lead to better treatment options.

The service positions itself as a leader in cancer detection innovation, emphasizing early intervention and advanced technology.

The target users include oncologists, healthcare providers, and individuals seeking early cancer detection, particularly those with a family history of cancer or other risk factors.

Get in touch

• Multi-cancer detection

• Early detection

• Blood test

• Methylation analysis

Detect cancer early, when it can be cured.

Innovative, compassionate, authoritative

The Galleri® Test is unique in its ability to screen for multiple cancers simultaneously using a single blood test, targeting cancers that currently lack effective screening methods.

GRAIL is positioned as a cutting-edge healthcare company dedicated to transforming cancer screening and improving patient outcomes through innovative solutions.

2016-01-01

• Jeff Huber

• Mostafa Ronaghi